We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Steve Abrams

Partner
Philadelphia

Steve Abrams

As a member of the Global Life Sciences Leadership Team, Steve Abrams works with clients in many areas of the life sciences ecosystem, such as oncology therapies, pain products, dermatology therapies, vaccines, diagnostics, medical devices and drug/device combinations, orphan drugs, and gene therapies. He also counsels a variety of companies that provide services to the life sciences industry.

Steve has successfully negotiated and completed a range of life sciences transactions, with a particular focus on capital market offerings (IPOs, follow-on offerings, ATMs, RDOs, PIPES, and private placements), collaboration/licensing transactions, and M&A transactions. Additionally, he regularly advises public and privately held clients, including boards of directors, on securities, governance, transactional, and a range of other complex issues.

Steve is a member of the board of directors of inTEST Corporation (NASDAQ: INTT) and is also a member of inTEST's Executive, Audit, and Compensation Committees. He is Chair of its Nominating Committee as well. Steve is also a member of the board of directors of the National Association of Corporate Directors - Philadelphia Chapter. He has lectured in front of various groups and published articles on securities, governance, and M&A issues.

Representative Experience

Represented a pre-clinical-stage pharmaceutical company in its US$48m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*

Represented a clinical-stage pharmaceutical company in its US$80m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*

Represented a NASDAQ Global Market developer and supplier of injectable drug delivery systems in a US$45m underwritten offering of common stock.*

Represented a clinical-stage biopharmaceutical company in its US$40m at-the-market equity program led by Cowen and Company.*

Represented a publicly traded clinical stage pharmaceutical company in a US$65.6m underwritten offering of common stock.*

Represented a provider of integrated clinical documentation solutions for the U.S. healthcare system in a US$130m acquisition.*

Represented a provider of integrated promotional outsource services to life sciences companies in its US$55m acquisition.*

*Matter handled prior to joining Hogan Lovells.

Education and admissions

Education

  • J.D., cum laude, University of Pennsylvania Law School, 1995
  • B.A., summa cum laude, Rutgers, The State University of New Jersey, 1990

Bar admissions and qualifications

  • Pennsylvania
  • New Jersey
Loading data